The novel PARP inhibitor no. 123 induces DNA damage and activates cGAS-STING signaling to suppress cervical cancer
Compound No. 123, a novel PARP inhibitor derived from thiosemicarbazone dimers, was investigated for its antitumor activity against cervical cancer and its ability to modulate antitumor immunity via the cGAS-STING pathway. No. 123 potently inhibited PARP1 enzymatic activity (IC 50 = 73.18 ± 12.04 nM) and showed a computationally predicted binding mode within the PARP1 catalytic domain through multiple interactions with key residues including ASP-807, GLN-717, LYS-893, GLU-809, and ILE-879. In HeLa cells, No. 123 suppressed proliferation by inducing G2/M phase arrest and triggered mitochondrial-mediated apoptosis through ROS generation and modulation of the Bax/Bcl-2 ratio. Importantly, No. 123 induced DNA damage, as evidenced by increased γH2AX expression, leading to activation of the cGAS-STING pathway, as evidenced by increased phosphorylation of STING, TBK1, and IRF3. In a murine cervical cancer model, oral administration of No. 123 significantly suppressed tumor growth (inhibition rate: 92%) and modulated antitumor immunity, as evidenced by increased dendritic cell maturation and altered tumor-infiltrating immune cell composition. In vivo mechanistic studies confirmed that No. 123 induced DNA damage (increased γH2AX expression) and activated the cGAS-STING pathway, leading to upregulated expression of downstream inflammatory cytokines in tumor tissues. Notably, No. 123 exhibited a favorable safety profile with no apparent organ toxicity or alterations in serum ALT/AST levels. These findings establish No. 123 as a promising therapeutic candidate for cervical cancer that exerts antitumor effects through a dual mechanism involving direct cytotoxicity and cGAS-STING-mediated immune activation, independent of canonical HRD/BRCA mutations.
Authors
- Fengshu Fei
- Xin Wang (ORCID: https://orcid.org/0000-0002-7296-9406)
- Fangyu Jiao
- Qianlong Fu
- Jianting Huang
- Shiyu Ma
- Chuanlong Guo
- Nan Wang
- Fangwei Zhang
Institutions
- Qingdao University of Science and Technology (CN)
- Shandong University (CN)
Publication Details
- Journal
- Cell Biology and Toxicology
- Published
- 2026-11-12
- DOI
- https://doi.org/10.1007/s10565-026-10315-8
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province